Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia
Annals of Hematology · 09.05.2026 · 105 (7)
DOI: 10.1007/s00277-026-07052-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 09.05.2026. Verfasst von Samah Nassereddine und 13 weiteren Autor:innen. Beteiligte Einrichtung: GW Cancer Center, George Washington University, Washington, DC, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Time-to-Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is considered an oncologic emergency, yet the optimal timing for treatment initiation remains uncertain. We conducted a multi-institutional retrospective study of 698 adults with newly diagnosed AML presenting to four academic centers across the United States. Diagnosis-to-treatment intervals (DTI) were categorized as < 5 days, 5–10 days, and > 10 days. Outcomes were analyzed using multivariable models adjusting for age, treatment intensity, ELN 2017 risk classification, and white blood cell count. Among younger patients, DTI was not associated with differences in survival outcomes. In contrast, older patients demonstrated improved survival with delayed treatment (DTI > 10 days), particularly those with lower white blood cell counts. No adverse effects from treatment delay were observed in younger cohorts. This retrospective study showed that prolonged DTI is associated with improved survival in older adults with newly diagnosed AML, challenging the traditional assumption that immediate therapy universally improves outcomes. These findings underscore the importance of individualized treatment timing in the era of precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GW Cancer Center, George Washington University, Washington, DC, USA.
- Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
- Department of Medicine, Georgetown University, Washington, DC, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Catherine.lai@pennmedicine.upenn.edu.
Zitieren
APA
Nassereddine, S., Feng, Y., Selep, J., El Chaer, F., Wells, L., Elsarrag, R., Doucette, K., Aggarwal, V., Williams, L., Tabbara, I., Liu, S., Diao, G., Percival, M. M., & Lai, C. (2026). Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07052-7
Vancouver
Nassereddine S, Feng Y, Selep J, El Chaer F, Wells L, Elsarrag R, et al. Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07052-7
BibTeX
@article{Nassereddine2026,
author = {Nassereddine, Samah and Feng, Yuan and Selep, Jordan and El Chaer, Firas and Wells, Leah and Elsarrag, Ramey and Doucette, Kimberly and Aggarwal, Vanya and Williams, Lacey and Tabbara, Imad and Liu, Shanshan and Diao, Guoquing and Percival, Mary-Elizabeth M and Lai, Catherine},
title = {Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {7},
doi = {10.1007/s00277-026-07052-7}
}
EUVIMED